Endocrinology

After Janssen's submission of an sNDA in March, results of the CREDENCE subgroup analyses were among the most anticipated presentations at ADA 2019.

A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.

FDA has announced the approval of liraglutide injections for treatment of type 2 diabetes among pediatric patients.

A 6-month study examining the effects of hepatic-directed prandial insulin in patients with type 1 diabetes mellitus was presented at ADA 2019.

Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.

A study analyzing the renal outcomes of the DECLARE-TIMI 58 trial were presented at ADA 2019 in San Francisco, CA.

A new study shows patients with T1D and comorbid cardiovascular disease face a signficantly greater cost of care.

A recent analysis of the BRIGHT trial examining renal function of insulin glargine 300u/mL versus insulin degludec 100u/mL was presented at ADA 2019.

After making the rounds at ADA 2019, Patrick Burgess, MD, discusses what he thinks is the most important discussion taking place at this year's conference and the biggest challenge facing diabetes patients.

A meta-analysis of 3 real-world studies into the effectiveness of Abbot's FreeStyle Libre Flash Glucose Monitoring System at ADA 2019.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.

A high consumption of ultra-processed foods (i.e. almost any consumable food item, except fresh fruits and vegetables) is associated with an increased risk of cardiovascular disease and mortality, show two studies in BMJ.

A new study from ADA showed the investigative monoclonal antibody suppressed development and diagnosis of T1D in at-risk patients.

A new retrospective cohort analysis found that patients with type 2 diabetes generally have about 12 months following BI initiation to achieve A1c < 7.0%.

Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.

A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.

A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.

The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.

An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?

The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

New findings show the controversial 2018 blood sugar control recommendations are associated with cost benefits for 3 subgroups of affected T2D patients.

A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.

Welcome to Endocrinology Network, an online publication of the ModernMedicine Network for healthcare professionals. What's inside? Research news summaries, conference coverage, case studies, photo clinics and more. We welcome contributing articles from physicians, nurses and other healthcare professionals.